Will Personalized Medicine Mean Higher Costs for Consumers?

Main|Search|PHGKB




Last Posted: Mar 02, 2018

---

• Will Personalized Medicine Mean Higher Costs for Consumers?  
  M Geruso et al, Harvard Business Review, Mar 1, 2018
• Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?  
  Hughes Dyfrig A et al. Clinical pharmacology and therapeutics 2018 Feb
• Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.  
  Dinh Tuan A et al. Cancer prevention research (Philadelphia, Pa.) 2011 Jan 4(1) 9-22
• Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.  
  Shen Chan et al. Oncotarget 2016 Nov 7(44) 71686-71695
• Screening for Lynch syndrome: it is time to shift the focus.  
  Kidambi Trilokesh D et al. Digestive diseases and sciences 2015 Feb 60(2) 586-7
• Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.  
  Ladabaum Uri et al. Annals of internal medicine 2011 Jul 155(2) 69-79

more